On Friday, Amicus Therapeutics, Inc. (NASDAQ:FOLD)’s shares inclined 3.44% to $12.64.
Amicus Therapeutics, Inc. (FOLD) has presented a marketing authorization application (MAA) to request full approval of the oral small molecule pharmacological chaperone Galafold (migalastat HCl) for Fabry patients who have amenable genetic mutations. The brand name Galafold has been approved by both the European Medicines Agency (EMA) in addition to the U.S. Food and Drug Administration (FDA).
As formerly declared, Galafold is the first investigational Fabry drug to be granted Accelerated Assessment in the EU. Under Accelerated Assessment, the Committee for Medicinal Products for Human Use (CHMP) may shorten the MAA review period from 210 days, under standard review, to 150 days under Accelerated Assessment. The CHMP opinion is then reviewed by the European Commission, which generally issues a final decision on EU approval within three months. The MAA submission will be reviewed in the Centralized Procedure, which if authorized, provides a marketing license valid in all 28 EU member states. Once authorized, Amicus would then start the country-by-country reimbursement approval process.
Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for various rare and orphan diseases. Its product candidate is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Invesco Mortgage Capital Inc (NYSE:IVR)’s shares dropped -1.53% to $15.43.
Invesco Mortgage Capital Inc (IVR) is planned to present at the 2015 Morgan Stanley Financials Conference to be held in New York, NY on June 9, 2015, at about 2:25 pm ET. John Anzalone, Chief Investment Officer, is planned to speak.
Invesco Mortgage Capital Inc., a real estate investment trust, focuses on investing in, financing, and managing residential and commercial mortgage-backed securities and mortgage loans.
At the end of Friday’s trade, Xenia Hotels & Resorts Inc (NYSE:XHR)‘s shares surged 0.76% to $22.61.
Xenia Hotels & Resorts Inc (XHR) declared that its Board of Directors has authorized a cash dividend of $0.23 per share of the Company’s common stock for the second quarter of 2015. The dividend will be paid on July 15, 2015 to all holders of record of the Company’s common stock as of the close of business on June 30, 2015.
The Board of Directors also authorized a cash dividend for a partial six month period of $61.11 per share of the Company’s 12.5% Series A Cumulative Non-Voting Preferred Stock for the first six months of 2015. The dividend will be paid on June 30, 2015 to all holders of record of the preferred stock as of the close of business on June 15, 2015.
Xenia Hotels & Resorts, Inc. operates as a self-advised and self-administered REIT that invests in full service hotels in the United States. As of December 31, 2014, it owned 46 hotels comprising 12,636 rooms across 19 states and the District of Columbia. The company is based in Orlando, Florida.
Hershey Co (NYSE:HSY), ended its Friday’s trading session with -0.45% loss, and closed at $90.87.
Hershey Co (HSY) declared that Humberto (Bert) P. Alfonso, 57, President, International, intends to retire from the company by the end of June. The company is working with Alfonso to ensure a seamless transition and anticipates to declare its succession plan at the end of the month.
The Hershey Company manufactures, imports, markets, distributes, and sells confectionery products. The company operates through two segments, North America; and International and Other. It offers chocolate and sugar confectionery products; pantry items, such as baking ingredients, toppings, sundae syrups, and beverages; snack items, counting spreads; and gum and mint refreshment products comprising chewing gums and bubble gums.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
